PMV Pharmaceuticals, Inc. financial data

Symbol
PMVP on Nasdaq
Industry
Pharmaceutical Preparations
Location
One Research Way, Princeton, NJ
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.73K % -17.7%
Debt-to-equity 10.9 % +8.43%
Return On Equity -22 % +29.3%
Return On Assets -19.8 % +29.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 51.5M shares +6.33%
Common Stock, Shares, Outstanding 51.5M shares +11.7%
Entity Public Float 209M USD -61.5%
Weighted Average Number of Shares Outstanding, Basic 51.5M shares +12.4%
Weighted Average Number of Shares Outstanding, Diluted 51.5M shares +12.4%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 54.8M USD -4.9%
General and Administrative Expense 22.1M USD -9.76%
Operating Income (Loss) -76.9M USD +6.35%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -65.1M USD +12.3%
Income Tax Expense (Benefit) 4K USD
Net Income (Loss) Attributable to Parent -48.9M USD +34.1%
Earnings Per Share, Basic -0.96 USD/shares +40.7%
Earnings Per Share, Diluted -0.96 USD/shares +40.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 48.5M USD -28.9%
Marketable Securities, Current 164M USD +38.3%
Cash, Cash Equivalents, and Short-term Investments 213M USD -2.71%
Assets, Current 219M USD +14.9%
Property, Plant and Equipment, Net 10.5M USD -5.44%
Operating Lease, Right-of-Use Asset 8.04M USD -7.92%
Other Assets, Noncurrent 182K USD +0.55%
Assets 238M USD -1.93%
Accounts Payable, Current 4.53M USD +29.9%
Accrued Liabilities, Current 5.7M USD -28.2%
Liabilities, Current 11.4M USD -0.54%
Operating Lease, Liability, Noncurrent 11.8M USD -8.65%
Liabilities 23.2M USD -4.85%
Accumulated Other Comprehensive Income (Loss), Net of Tax -185K USD +43.6%
Retained Earnings (Accumulated Deficit) -326M USD -17.6%
Stockholders' Equity Attributable to Parent 214M USD -1.6%
Liabilities and Equity 238M USD -1.93%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -16.2M USD -7.81%
Net Cash Provided by (Used in) Financing Activities 12K USD -90.6%
Net Cash Provided by (Used in) Investing Activities 26.2M USD -47.3%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 51.5M shares +11.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9.95M USD -71.3%
Deferred Tax Assets, Valuation Allowance 93.8M USD +25.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.93 pure
Deferred Tax Assets, Gross 96.4M USD +24.1%
Operating Lease, Liability 13M USD +0.09%
Depreciation 1.45M USD +111%
Payments to Acquire Property, Plant, and Equipment 594K USD +281%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -48.7M USD +33.6%
Property, Plant and Equipment, Gross 14.5M USD +4.87%
Operating Lease, Liability, Current 1.15M USD +6294%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.19M USD -18.8%
Deferred Tax Assets, Operating Loss Carryforwards 56.7M USD +14.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 3.17M USD +30.2%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.58M USD -5.92%
Share-based Payment Arrangement, Expense 11.7M USD +0.71%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%